Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response

A. J. Mathew; M. L. Lund; M. P. Pedersen; S. H. Rasmussen; B. Glintborg; A. G. Loft; M. J. Nissen; B. Möller; A. M. Rodrigues; F. P. Santos; Z. Rotar; M. Tomšič; H. Relas; R. Peltomaa; B. Gudbjornsson; T. J. Löve; S. B. Kocaer; A. Koken Avsar; L. Midtbøll Ørnbjerg; M. Østergaard

doi:10.1080/03009742.2024.2336743

Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response

A. J. Mathew^*, M. L. Lund, M. P. Pedersen, S. H. Rasmussen, B. Glintborg, A. G. Loft, M. J. Nissen, B. Möller, A. M. Rodrigues, F. P. Santos, Z. Rotar, M. Tomšič, H. Relas, R. Peltomaa, B. Gudbjornsson, T. J. Löve, S. B. Kocaer, A. Koken Avsar, L. Midtbøll Ørnbjerg, M. Østergaard

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

5 Downloads (Pure)

Abstract

Objective
To explore the registration of enthesitis among biologic-naïve patients with psoriatic arthritis (PsA) initiating tumour necrosis factor inhibitor (TNFi) treatment across 12 European registries, compare the disease burden and patient-reported outcomes (PROs) between patients with and without enthesitis, and assess the enthesitis treatment response.

Method
Demographics, clinical characteristics, and PROs at first TNFi (TNFi-1) initiation (baseline) were assessed in patients with PsA, diagnosed by a rheumatologist, with versus without assessment of entheses and between those with versus without enthesitis. Enthesitis scores and resolution frequency were identified at follow-up.

Results
Of 10 547 patients in the European Spondyloarthritis (EuroSpA) Research Collaboration Network initiating TNFi, 1357 underwent evaluation for enthesitis. Eight registries included a validated scoring system for enthesitis. At baseline, 874 patients underwent entheses assessment [Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) 485 patients, Spondyloarthritis Research Consortium of Canada (SPARCC) 389 patients]. Enthesitis was detected by MASES in 170/485 (35%, mean score ± sd 3.1 ± 2.4) and by SPARCC in 236/389 (61%, 4 ± 3.4). Achilles enthesitis was most frequent, by both MASES (unilateral/bilateral 28%/9%) and SPARCC (48%/18%). MASES/SPARCC baseline and follow-up scores for TNFi-1 were available for 100/105 patients. Of these, 63 patients (63%) (MASES) and 46 (43.8%) (SPARCC) achieved resolution of enthesitis. The site-specific enthesitis resolution was overall lower at SPARCC sites (peripheral; 63–80%) than at MASES sites (mainly axial; 82–100%) following TNFi-1. Disease activity and PROs were worse in patients with versus without enthesitis.

Conclusion
Entheseal assessments are only registered in a minority of patients with PsA in routine care. When assessed, enthesitis was common, and a substantial proportion demonstrated resolution following treatment with TNFi-1.

Originalsprog	Engelsk
Bogserie	Scandinavian Journal of Rheumatology
Vol/bind	53
Udgave nummer	4
Sider (fra-til)	237-247
ISSN	0300-9742
DOI	https://doi.org/10.1080/03009742.2024.2336743
Status	Udgivet - 2024

Bibliografisk note

Funding Information:
The EuroSpA Research Collaboration Network was financially supported by Novartis Pharma AG. Novartis did not influence data collection, statistical analyses, manuscript preparation or decision to submit the manuscript. The outline of was drawn by Mr Rajkumar, Department of Anatomy, Christian Medical College, Vellore, India.

Publisher Copyright:
© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Adgang til dokumentet

10.1080/03009742.2024.2336743Licens: CC BY-NC-ND

FulltextForlagets udgivne version, 1,11 MBLicens: CC BY-NC-ND

Citationsformater

Mathew, A. J., Lund, M. L., Pedersen, M. P., Rasmussen, S. H., Glintborg, B., Loft, A. G., Nissen, M. J., Möller, B., Rodrigues, A. M., Santos, F. P., Rotar, Z., Tomšič, M., Relas, H., Peltomaa, R., Gudbjornsson, B., Löve, T. J., Kocaer, S. B., Avsar, A. K., Ørnbjerg, L. M., & Østergaard, M. (2024). Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response. Scandinavian Journal of Rheumatology, 53(4), 237-247. https://doi.org/10.1080/03009742.2024.2336743

Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors : clinical burden, patient-reported outcomes, and treatment response. / Mathew, A. J.; Lund, M. L.; Pedersen, M. P.; Rasmussen, S. H.; Glintborg, B.; Loft, A. G.; Nissen, M. J.; Möller, B.; Rodrigues, A. M.; Santos, F. P.; Rotar, Z.; Tomšič, M.; Relas, H.; Peltomaa, R.; Gudbjornsson, B.; Löve, T. J.; Kocaer, S. B.; Avsar, A. Koken; Ørnbjerg, L. Midtbøll; Østergaard, M.

I: Scandinavian Journal of Rheumatology, Bind 53, Nr. 4, 2024, s. 237-247.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Mathew, AJ, Lund, ML, Pedersen, MP, Rasmussen, SH, Glintborg, B, Loft, AG, Nissen, MJ, Möller, B, Rodrigues, AM, Santos, FP, Rotar, Z, Tomšič, M, Relas, H, Peltomaa, R, Gudbjornsson, B, Löve, TJ, Kocaer, SB, Avsar, AK, Ørnbjerg, LM & Østergaard, M 2024, 'Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response', Scandinavian Journal of Rheumatology, bind 53, nr. 4, s. 237-247. https://doi.org/10.1080/03009742.2024.2336743

Mathew AJ, Lund ML, Pedersen MP, Rasmussen SH, Glintborg B, Loft AG et al. Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response. Scandinavian Journal of Rheumatology. 2024;53(4):237-247. https://doi.org/10.1080/03009742.2024.2336743

Mathew, A. J. ; Lund, M. L. ; Pedersen, M. P. ; Rasmussen, S. H. ; Glintborg, B. ; Loft, A. G. ; Nissen, M. J. ; Möller, B. ; Rodrigues, A. M. ; Santos, F. P. ; Rotar, Z. ; Tomšič, M. ; Relas, H. ; Peltomaa, R. ; Gudbjornsson, B. ; Löve, T. J. ; Kocaer, S. B. ; Avsar, A. Koken ; Ørnbjerg, L. Midtbøll ; Østergaard, M. / Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors : clinical burden, patient-reported outcomes, and treatment response. I: Scandinavian Journal of Rheumatology. 2024 ; Bind 53, Nr. 4. s. 237-247.

@article{113d03a360294ea080e9e24dda9e1dc3,

title = "Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response",

abstract = "Objective: To explore the registration of enthesitis among biologic-na{\"i}ve patients with psoriatic arthritis (PsA) initiating tumour necrosis factor inhibitor (TNFi) treatment across 12 European registries, compare the disease burden and patient-reported outcomes (PROs) between patients with and without enthesitis, and assess the enthesitis treatment response. Method: Demographics, clinical characteristics, and PROs at first TNFi (TNFi-1) initiation (baseline) were assessed in patients with PsA, diagnosed by a rheumatologist, with versus without assessment of entheses and between those with versus without enthesitis. Enthesitis scores and resolution frequency were identified at follow-up. Results: Of 10 547 patients in the European Spondyloarthritis (EuroSpA) Research Collaboration Network initiating TNFi, 1357 underwent evaluation for enthesitis. Eight registries included a validated scoring system for enthesitis. At baseline, 874 patients underwent entheses assessment [Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) 485 patients, Spondyloarthritis Research Consortium of Canada (SPARCC) 389 patients]. Enthesitis was detected by MASES in 170/485 (35%, mean score ± sd 3.1 ± 2.4) and by SPARCC in 236/389 (61%, 4 ± 3.4). Achilles enthesitis was most frequent, by both MASES (unilateral/bilateral 28%/9%) and SPARCC (48%/18%). MASES/SPARCC baseline and follow-up scores for TNFi-1 were available for 100/105 patients. Of these, 63 patients (63%) (MASES) and 46 (43.8%) (SPARCC) achieved resolution of enthesitis. The site-specific enthesitis resolution was overall lower at SPARCC sites (peripheral; 63–80%) than at MASES sites (mainly axial; 82–100%) following TNFi-1. Disease activity and PROs were worse in patients with versus without enthesitis. Conclusion: Entheseal assessments are only registered in a minority of patients with PsA in routine care. When assessed, enthesitis was common, and a substantial proportion demonstrated resolution following treatment with TNFi-1.",

author = "Mathew, {A. J.} and Lund, {M. L.} and Pedersen, {M. P.} and Rasmussen, {S. H.} and B. Glintborg and Loft, {A. G.} and Nissen, {M. J.} and B. M{\"o}ller and Rodrigues, {A. M.} and Santos, {F. P.} and Z. Rotar and M. Tom{\v s}i{\v c} and H. Relas and R. Peltomaa and B. Gudbjornsson and L{\"o}ve, {T. J.} and Kocaer, {S. B.} and Avsar, {A. Koken} and {\O}rnbjerg, {L. Midtb{\o}ll} and M. {\O}stergaard",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",

year = "2024",

doi = "10.1080/03009742.2024.2336743",

language = "English",

volume = "53",

pages = "237--247",

journal = "Acta rheumatologica Scandinavica",

issn = "0301-3847",

publisher = "Taylor & Francis",

number = "4",

}

TY - JOUR

T1 - Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors

T2 - clinical burden, patient-reported outcomes, and treatment response

AU - Mathew, A. J.

AU - Lund, M. L.

AU - Pedersen, M. P.

AU - Rasmussen, S. H.

AU - Glintborg, B.

AU - Loft, A. G.

AU - Nissen, M. J.

AU - Möller, B.

AU - Rodrigues, A. M.

AU - Santos, F. P.

AU - Rotar, Z.

AU - Tomšič, M.

AU - Relas, H.

AU - Peltomaa, R.

AU - Gudbjornsson, B.

AU - Löve, T. J.

AU - Kocaer, S. B.

AU - Avsar, A. Koken

AU - Ørnbjerg, L. Midtbøll

AU - Østergaard, M.

PY - 2024

Y1 - 2024

N2 - Objective: To explore the registration of enthesitis among biologic-naïve patients with psoriatic arthritis (PsA) initiating tumour necrosis factor inhibitor (TNFi) treatment across 12 European registries, compare the disease burden and patient-reported outcomes (PROs) between patients with and without enthesitis, and assess the enthesitis treatment response. Method: Demographics, clinical characteristics, and PROs at first TNFi (TNFi-1) initiation (baseline) were assessed in patients with PsA, diagnosed by a rheumatologist, with versus without assessment of entheses and between those with versus without enthesitis. Enthesitis scores and resolution frequency were identified at follow-up. Results: Of 10 547 patients in the European Spondyloarthritis (EuroSpA) Research Collaboration Network initiating TNFi, 1357 underwent evaluation for enthesitis. Eight registries included a validated scoring system for enthesitis. At baseline, 874 patients underwent entheses assessment [Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) 485 patients, Spondyloarthritis Research Consortium of Canada (SPARCC) 389 patients]. Enthesitis was detected by MASES in 170/485 (35%, mean score ± sd 3.1 ± 2.4) and by SPARCC in 236/389 (61%, 4 ± 3.4). Achilles enthesitis was most frequent, by both MASES (unilateral/bilateral 28%/9%) and SPARCC (48%/18%). MASES/SPARCC baseline and follow-up scores for TNFi-1 were available for 100/105 patients. Of these, 63 patients (63%) (MASES) and 46 (43.8%) (SPARCC) achieved resolution of enthesitis. The site-specific enthesitis resolution was overall lower at SPARCC sites (peripheral; 63–80%) than at MASES sites (mainly axial; 82–100%) following TNFi-1. Disease activity and PROs were worse in patients with versus without enthesitis. Conclusion: Entheseal assessments are only registered in a minority of patients with PsA in routine care. When assessed, enthesitis was common, and a substantial proportion demonstrated resolution following treatment with TNFi-1.

AB - Objective: To explore the registration of enthesitis among biologic-naïve patients with psoriatic arthritis (PsA) initiating tumour necrosis factor inhibitor (TNFi) treatment across 12 European registries, compare the disease burden and patient-reported outcomes (PROs) between patients with and without enthesitis, and assess the enthesitis treatment response. Method: Demographics, clinical characteristics, and PROs at first TNFi (TNFi-1) initiation (baseline) were assessed in patients with PsA, diagnosed by a rheumatologist, with versus without assessment of entheses and between those with versus without enthesitis. Enthesitis scores and resolution frequency were identified at follow-up. Results: Of 10 547 patients in the European Spondyloarthritis (EuroSpA) Research Collaboration Network initiating TNFi, 1357 underwent evaluation for enthesitis. Eight registries included a validated scoring system for enthesitis. At baseline, 874 patients underwent entheses assessment [Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) 485 patients, Spondyloarthritis Research Consortium of Canada (SPARCC) 389 patients]. Enthesitis was detected by MASES in 170/485 (35%, mean score ± sd 3.1 ± 2.4) and by SPARCC in 236/389 (61%, 4 ± 3.4). Achilles enthesitis was most frequent, by both MASES (unilateral/bilateral 28%/9%) and SPARCC (48%/18%). MASES/SPARCC baseline and follow-up scores for TNFi-1 were available for 100/105 patients. Of these, 63 patients (63%) (MASES) and 46 (43.8%) (SPARCC) achieved resolution of enthesitis. The site-specific enthesitis resolution was overall lower at SPARCC sites (peripheral; 63–80%) than at MASES sites (mainly axial; 82–100%) following TNFi-1. Disease activity and PROs were worse in patients with versus without enthesitis. Conclusion: Entheseal assessments are only registered in a minority of patients with PsA in routine care. When assessed, enthesitis was common, and a substantial proportion demonstrated resolution following treatment with TNFi-1.

U2 - 10.1080/03009742.2024.2336743

DO - 10.1080/03009742.2024.2336743

M3 - Journal article

C2 - 38771017

AN - SCOPUS:85193698223

VL - 53

SP - 237

EP - 247

JO - Acta rheumatologica Scandinavica

JF - Acta rheumatologica Scandinavica

SN - 0301-3847

IS - 4

ER -